NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/27/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization182.39 mln
Float11.84 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
43.22
Transformational upside
Relative Strength
23
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-284
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Immunic Inc. is a US and Germany-based biotech company founded in 2016 that creates oral treatments for chronic inflammatory and autoimmune conditions. Its most advanced drug candidate, IMU-838, is currently in Phase 2 and Phase 3 trials targeting multiple sclerosis and ulcerative colitis. The company is also working on IMU-856, which enters Phase 2 trials to help restore gut barrier function in patients with conditions such as celiac disease and irritable bowel syndrome, as well as IMU-381, an early-stage treatment for gastrointestinal diseases.
